ORCID Profile
0000-0002-6071-4318
Current Organisation
UNSW Sydney
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: IEEE
Date: 11-2018
Publisher: Springer Science and Business Media LLC
Date: 05-05-2018
DOI: 10.1007/S00592-018-1151-X
Abstract: To compare functional and anatomical outcomes of continued anti-vascular endothelial growth factor (VEGF) therapy versus dexamethasone (DEX) implant in eyes with refractory diabetic macular edema (DME) after three initial anti-VEGF injections in a real-world setting. To be included in this retrospective multicenter, case-control study, eyes were required: (1) to present with early refractory DME, as defined by visual acuity (VA) gain ≤ 5 letters or reduction in central subfield thickness (CST) ≤ 20%, after a loading phase of anti-VEGF therapy (three monthly injections) and (2) to treat further with (a) anti-VEGF therapy or (b) DEX implant. Main outcome measures were change in visual acuity (VA) and central subfield thickness (CST) at 12 months. Due to imbalanced baseline characteristics, a matched anti-VEGF group was formed by only keeping eyes with similar baseline characteristics as those in the DEX group. A total of 110 eyes from 105 patients were included (anti-VEGF group: 72 eyes, DEX group: 38 eyes). Mean change in VA at 12 months was - 0.4 ± 10.8 letters (anti-VEGF group), and + 6.1 ± 10.6 letters (DEX group) (P = 0.004). Over the same period, mean change in CST was + 18.3 ± 145.9 µm (anti-VEGF group) and - 92.8 ± 173.6 µm (DEX group) (P < 0.001). Eyes in the DEX group were more likely to gain ≥ 10 letters (OR 3.71, 95% CI 1.19-11.61, P = 0.024) at month 12. In a real-world setting, eyes with DME considered refractory to anti-VEGF therapy after three monthly injections which were switched to DEX implant and had better visual and anatomical outcomes at 12 months than those that continued treatment with anti-VEGF therapy.
Publisher: IOP Publishing
Date: 11-2019
DOI: 10.1088/1757-899X/674/1/012036
Abstract: The optimal control of distribution system operation is presented in this paper. The objective of the control is minimum real power loss simultaneously achieved with voltage profile improvement. The distribution system equipped with Load Tap Changer (LTC) and switchable Shunt Capacitors is optimally controlled by determining the tap position of LTC and switching status of Shunt Capacitor at every hour for the 24-hour period. Two Genetic Algorithms (GAs) are developed for load curve partition and hourly components status determination. The performance of GA for components optimal scheduling is further enhanced by integrating Fuzzy Strategies in fitness evaluation and constraints satisfaction. The scheme of Fuzzy Convex Decision Making (FCDM) that provides flexible objective achievement and soft constraints is employed. This enables considering more extensive solutions that may lead to better optimal control. The proposed control strategy is implemented on 30-bus distribution system and the system improvements are observed. The enhancement of fuzzy integration is highlighted.
Publisher: IEEE
Date: 08-2018
Publisher: IEEE
Date: 03-2012
Publisher: IEEE
Date: 10-2011
Publisher: IOP Publishing
Date: 09-10-2018
Publisher: Elsevier BV
Date: 02-2018
DOI: 10.1016/J.OPHTHA.2017.08.031
Abstract: Identification and characterization of patients with diabetic macular edema (DME) are important for in idualizing treatment and optimizing outcome. We investigated OCT biomarkers for DME treated by intravitreal dexamethasone (DEX) implant. Multicenter, retrospective, observational cohort study. A total of 299 eyes from 284 patients treated with DEX implant for DME (naïve, n = 209 refractory, n = 90). Baseline best-corrected visual acuity (BCVA) was between 0.3 and 1.0 on a logarithm of minimum angle of resolution visual chart. The OCT scans previous to DEX implants were evaluated for submacular fluid, size and location of cystoid changes, inner segment-outer segment (IS-OS) continuity, quantity and location of hyperreflective foci (HRF), vitreomacular interface abnormalities, and epiretinal membrane. The BCVA and central macular thickness were recorded at baseline and at 1, 2, and 4 months after treatment with DEX implants. Correlations between OCT measures and visual outcome were analyzed using the generalized estimating equations procedure. The correlation between spectral-domain (SD) OCT measures at baseline and BCVA response (mean change from baseline categorized improvement [<5, 5-9, or ≥10 Early Treatment Diabetic Retinopathy Study letters] in BCVA) after treatment with a DEX implant. The presence of subretinal fluid (odds ratio [OR], 1.98 95% confidence interval [CI], 1.23-3.20 P = 0.01), absence of HRF (OR, 3.66 95% CI, 1.40-9.62 P = 0.01), and integrity of the IS-OS layer (OR, 2.09 95% CI, 1.30-3.37 P = 0.003) were all predictive of better visual outcome after treatment with DEX implants. Although eyes with naïve DME gained more vision than refractory eyes (P < 0.001), the predictive value of OCT findings did not differ according to this classification. Spectral-domain OCT is useful in identifying various imaging findings in DME. Among eyes with DME, those with submacular fluid, no HRF, and a continuous IS-OS layer responded better to DEX implants than those without these features. These findings call for further study of combinations of OCT and metabolic biomarkers.
Publisher: Universitas Ahmad Dahlan
Date: 10-2019
No related grants have been discovered for Ermete Giancipoli.